MY169750A - Tablet containing 1-cyclopropyl-8-(difluoromethoxy)-7-[(1r)-1-methyl-2, 3-dihydro-1h-isoindole-5-yl]-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid methanesulfonate hydrate - Google Patents

Tablet containing 1-cyclopropyl-8-(difluoromethoxy)-7-[(1r)-1-methyl-2, 3-dihydro-1h-isoindole-5-yl]-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid methanesulfonate hydrate

Info

Publication number
MY169750A
MY169750A MYPI2014701375A MYPI2014701375A MY169750A MY 169750 A MY169750 A MY 169750A MY PI2014701375 A MYPI2014701375 A MY PI2014701375A MY PI2014701375 A MYPI2014701375 A MY PI2014701375A MY 169750 A MY169750 A MY 169750A
Authority
MY
Malaysia
Prior art keywords
tablet
dihydroquinoline
difluoromethoxy
cyclopropyl
dihydro
Prior art date
Application number
MYPI2014701375A
Inventor
Kakuda Sahoe
Miyazaki Tsutomu
Okada Kotaro
Original Assignee
Fujifilm Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Toyama Chemical Co Ltd filed Critical Fujifilm Toyama Chemical Co Ltd
Publication of MY169750A publication Critical patent/MY169750A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

(1) A tablet according to the present invention has a percentage content of l-cyclopropyl-8-(difluoromethoxy)-7-[(l R)-1-methyl-2, 3-dihydro-lH-isoindol-5- yl]-4-oxo-l, 4-dihydroquinoline-3-carboxylic acid methanesulfonate hydrate of between 80 wt% and 97.5 wt%. (2) The tablet is smaller in size than commercially available Geninax tablets 200mg. (3) As a result, drug compliance is improved, (4) the tablet is excellent in dissolution, and (5) the tablet is excellent in hardness and friability. (6) As a result, the present invention withstands film coating and transportation, and is useful as a tablet of methanesulfonate hydrate of chemical compound A.
MYPI2014701375A 2011-11-30 2012-11-29 Tablet containing 1-cyclopropyl-8-(difluoromethoxy)-7-[(1r)-1-methyl-2, 3-dihydro-1h-isoindole-5-yl]-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid methanesulfonate hydrate MY169750A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011261727 2011-11-30

Publications (1)

Publication Number Publication Date
MY169750A true MY169750A (en) 2019-05-15

Family

ID=48535494

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2014701375A MY169750A (en) 2011-11-30 2012-11-29 Tablet containing 1-cyclopropyl-8-(difluoromethoxy)-7-[(1r)-1-methyl-2, 3-dihydro-1h-isoindole-5-yl]-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid methanesulfonate hydrate

Country Status (10)

Country Link
JP (1) JP6117112B2 (en)
CN (2) CN109662952A (en)
BR (1) BR112014012994A2 (en)
MX (1) MX350659B (en)
MY (1) MY169750A (en)
PH (1) PH12014501224B1 (en)
RU (1) RU2633477C2 (en)
SG (1) SG11201402597WA (en)
WO (1) WO2013081044A1 (en)
ZA (1) ZA201403942B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017073738A1 (en) * 2015-10-29 2017-05-04 日本臓器製薬株式会社 Tablet having fexofenadine as effective component thereof
WO2017188362A1 (en) * 2016-04-27 2017-11-02 富山化学工業株式会社 Tablet containing tosufloxacin tosilate, disintegrator and acidic amino acid
JP7058104B2 (en) * 2017-10-19 2022-04-21 日本化薬株式会社 Pharmaceutical tablets containing aprepitant as an active ingredient

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639458A (en) * 1985-01-22 1987-01-27 Merck & Co., Inc. Tablet and formulation
KR100650489B1 (en) * 1998-11-10 2006-11-28 바이엘 헬스케어 아게 Pharmaceutical Moxifloxacin Preparation
JP4370050B2 (en) * 2000-12-04 2009-11-25 大正製薬株式会社 Clarithromycin tablets and method for producing the same
EP1459739B1 (en) * 2003-03-19 2008-01-02 The Jordanian Pharmaceutical Manufacturing Co. Ltd. Non-hygroscopic pharmaceutical compositions containing non-hydrated quinoline carboxylic acids
JP4702763B2 (en) * 2003-07-30 2011-06-15 塩野義製薬株式会社 Stable tablets containing crystalline cellulose
MX2007001811A (en) * 2004-08-13 2007-03-26 Schering Plough Ltd Pharmaceutical formulation comprising an antibiotic, a triazole and a corticosteroid.
US20070249577A1 (en) * 2005-05-10 2007-10-25 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
FI20080352A0 (en) * 2008-05-09 2008-05-09 Atacama Labs Oy Process for preparing a tablet with high drug content
FI20080353A0 (en) * 2008-05-09 2008-05-09 Atacama Labs Oy Process for preparing a tablet with extra high drug content
JP2011068647A (en) * 2009-08-31 2011-04-07 Kowa Co Solid formulation containing aspartic acid or salt thereof
WO2011059075A1 (en) * 2009-11-13 2011-05-19 味の素株式会社 Glutamic acid-rich and arginine-rich preparation

Also Published As

Publication number Publication date
RU2014126094A (en) 2016-01-27
RU2633477C2 (en) 2017-10-12
CN104039322A (en) 2014-09-10
PH12014501224A1 (en) 2014-09-08
ZA201403942B (en) 2015-08-26
BR112014012994A2 (en) 2017-06-13
MX350659B (en) 2017-09-13
MX2014006378A (en) 2014-10-13
JP6117112B2 (en) 2017-04-19
JPWO2013081044A1 (en) 2015-04-27
SG11201402597WA (en) 2014-09-26
PH12014501224B1 (en) 2014-09-08
WO2013081044A1 (en) 2013-06-06
CN109662952A (en) 2019-04-23

Similar Documents

Publication Publication Date Title
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
JO3148B1 (en) Notch pathway signaling inhibitor compound
PH12015500587A1 (en) Combination of regorafenib and acetylsalicylic acid for treating cancer
PH12015500460B1 (en) Coated pharmaceutical composition containing regorafenib
GEP20217235B (en) Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
MX2013015287A (en) Topical ophthalmological pharmaceutical composition containing regorafenib.
MY169750A (en) Tablet containing 1-cyclopropyl-8-(difluoromethoxy)-7-[(1r)-1-methyl-2, 3-dihydro-1h-isoindole-5-yl]-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid methanesulfonate hydrate
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
PH12014502407A1 (en) New alfentanil composition for the treatment of acute pain
MX370184B (en) Pharmaceutical composition comprising fingolimod.
PH12017500536A1 (en) Solid pharmaceutical composition comprising amlodipine and losartan
CA2865484A1 (en) Stabilized controlled-release pharmaceutical composition comprising gliclazide
MX343986B (en) Stabilized pharmaceutical compositions comprising rasagiline salts.
TH153154A (en) Tablets with 1-cyclopropyl-8- (diffluoromethoxy) -7 - ((1R) -1-methyl-2,3-dihydro-1H-iso Indole-5-il) -4-oxo-1,4-dihydroquinoline-3-carboxylic acid, methane, sulfonic acid Hydrated
TN2013000515A1 (en) Notch pathway signaling inhibitor compound
GR1007907B (en) Pharmaceutical composition containing a phenocarbamate acetylcholinesterase inhibitor
MX2012014342A (en) Preparation of a levalbuterol salt.